Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 5.41%
As of Friday, October 16, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Commentary & Analysis
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 6.03%
As of Friday, October 09, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 5.25%
As of Wednesday, September 23, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Up 5.11%
As of Monday, September 21, ARS Pharmaceuticals, Inc.’s SPRY share price has surged by 5.11%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 5.34%
As of Tuesday, September 08, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $398.8 | $208.8 | 36% |
|
| Shares Out (Mil) | 99.3 | 53.9 | 62% |
|
| Institutional Ownership | 90.3% | 93.1% | 58% |
|
| Float (Mil) | 48.0 | 41.4 | 46% |
|
| Beta | 0.97 | 0.95 | 58% |
|
| Avg Daily Volume (000s) | 1,609 | 614 | 78% |
|
| Price Change (52-week) |
(63.5%) | 45.3% | 15% |
|
| Growth | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 36.5% | 12.8% | 92% |
|
| Net Income (5yr) | (174.5%) | (10.2%) | 0% |
|
| EPS (5yr) | (101.0%) | 15.7% | 1 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.333) | ($1.880) | ($0.897) | |
| Month Ago EPS | ($0.327) | ($1.870) | ($0.897) | |
| # Rev Up | 0 | 0 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.270) | ($1.720) | ($0.943) | |
| Year/Year Chg | (47.0%) | 8.0% | (94.0%) | |
| Financials | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $117 | $37 | 27% |
|
| Net Income (TTM) (Mil) | ($215) | ($44) | 6% |
|
| EPS (TTM) | ($2.174) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($196) | ($33) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($43) | $2 | 21% |
|
| Long-Term Debt (Q1) (Mil) | $172 | $4 | 48% |
|
| Enterprise Value (Q1) (Mil) | $590 | $174 | 35% |
|
| Valuation | SPRY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 30.85 | 2.09 | 98% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.3% | 66.0% | 71% |
|
| Net Margin | (184.2%) | (75.3%) | 5% |
|
| ROA | (76.5%) | (47.2%) | 7% |
|
| ROE | (210.3%) | (54.2%) | 4% |
|
| Liabilities to Assets | 95.0% | 29.1% | 92% |
|
| F-Score | 1 | 2 | 1% |
|
ARS Pharmaceuticals, Inc. did not pass any screens on 10/16/2026.
